// App-Quantinova.ai

THU0278 : RITUXIMAB IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: A POTENTIAL THERAPEUTIC OPTION

Researchers

Presenter

  • H. Berman

Principal Investigators

  • I. Rodriguez-Pinto

  • G. Espinosa

  • R. Cervera

Medical Centers

  • Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clinic, Barcelona, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Antiphospholipid syndrome

  • Lupus

  • Mucosa-associated lymphoid tissue lymphoma

  • Autoimmune sclerosing cholangitis

  • Venous thrombosis

  • Lymphomas

  • Trauma

  • Cryopyrin associated periodic syndrome

Biomarkers

  • B-lymphocyte antigen CD20

  • Immunoglobulin G

Drug/Treatment

  • Glucocorticoid

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved